TraumaCad ישראל - עברית - Ministry of Health

traumacad

voyant health ltd. - רופא - the traumacad program is indicated for assisting healthcare professionals in preoperative planning of orthopedic surgery. the device allows for overlaying of prosthesis templates on radiological images, and includes tools for performing measurements on the image and for positioning the template.

Disposable Reflective Marker Spheres ישראל - עברית - Ministry of Health

disposable reflective marker spheres

voyant health ltd. - צוות טכני - disposable reflective marker spheres are intended to detect instrument coordinates and patient position with diagnostic imaging during treatment

אפיניטור 5 מג ישראל - עברית - Ministry of Health

אפיניטור 5 מג

novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

אפיניטור 10 מג ישראל - עברית - Ministry of Health

אפיניטור 10 מג

novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

אפיניטור 2.5 מג ישראל - עברית - Ministry of Health

אפיניטור 2.5 מג

novartis israel ltd - everolimus - טבליה - everolimus 2.5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

אקטמרה 162 מג S.C. ישראל - עברית - Ministry of Health

אקטמרה 162 מג s.c.

roche pharmaceuticals (israel) ltd - tocilizumab - תמיסה להזרקה - tocilizumab 162 mg / 0.9 ml - tocilizumab

אברולימוס טבע   10  מג ישראל - עברית - Ministry of Health

אברולימוס טבע 10 מג

abic marketing ltd, israel - everolimus - טבליה - everolimus 10 mg - everolimus

אברולימוס טבע   2.5  מג ישראל - עברית - Ministry of Health

אברולימוס טבע 2.5 מג

abic marketing ltd, israel - everolimus - טבליה - everolimus 2.5 mg - everolimus

אברולימוס טבע   5 מג ישראל - עברית - Ministry of Health

אברולימוס טבע 5 מג

abic marketing ltd, israel - everolimus - טבליה - everolimus 5 mg - everolimus

אברולימוס טבע   7.5 מג ישראל - עברית - Ministry of Health

אברולימוס טבע 7.5 מג

abic marketing ltd, israel - everolimus - טבליה - everolimus 7.5 mg - everolimus